.. ,

(conditional)

LDL- () (.. ) (.. CRP)

LDL HDL-

Circulation 2000

Patient risk category

Defined as LDL-C Goal Previous ATP III SupportiveTrials

High Risk CHD or CHDRisk equivalent

Goal : < 100 mg/dl(Optional:< 70 mg/dl)Initiate: 100 mg/dl

( Optional:

>150 . , 20.

2 4

Eur Heart J. 2007;28(1):88-136

Eur Heart J. 2007;28(1):88-136

Seven Countries Study (40 59 )Aravanis C et al. Circulation 1970

1960

Athens Study ( )Moulopoulos et al, Am J Epidem 1987

1980 4% 6%

Aegaleo Study ( )Katsilambros N et al.

1990 4% 2%

Didima village Study ( )Stergiou GS et al. Am J Hypert 1999

1990

EPIC study ( )Trichopoulos D et al. Academy of Athens 2003

2000 7% 7%

CARDIO2000 study ( / )Panagiotakos DB et al., Prev Med 2003

2000 10%/25% 11%/31%

ATTICA study ( )Pitsavos C et al. Public Health 2004

2000 8% 6%

5- 2001 2006 2001-2006

, n 1514 1044

(%) :

36.6 46.5 8.8 100

39.9 57.2 23.7 100

8.0 12.8 5.8 100

20.8 20.1 21.8 100

( ) 47.2 38.9 16.8 100

58.7 69.0 30.4 100

, n 1528 1057

(%) :

23.7 34.0 10.2 100

35.2 48.3 17.7 100

5.8 10.4 5.3 100

15.9 18.3 11.9 100

39.6 36.9 19.9 100

61.8 73.2 29.4 100

ATTICA STUDY

: , , , , - ,

.

Euro Heart Survey(2004), 22% ,

Eur Heart J, 2004 Nov;25(21):1880-90

OGTT:ORAL GLUCOSE TOLERANCE TEST IFG:IMPAIRED FASTING GLUCOSE IGT: IMPAIRED GLUCOSE TOLERANCE

Euro Heart Survey

Euro Heart Survey

OGTT: FGP:

Euro Heart Survey , , , , , .Eur Heart J, 2004 Nov;25(21):1880-90

1 4

The ATTICA Study: Vasc Med. 2008;13(2):113-21.

, , , .

,

,

1. 2. 3.

- -

-

P-IIb/IIIa

(TXA2) (ADP),

1. NF-kB

2. ( PKC)

3.

- (AGEs)

-

LDL

( PGF2a) -

(-)

( NO, , , , II, )

NO, ,

.

-ASA ()

(GP) IIb/

IIIa

-ASA ()

(GP) IIb/

IIIa

-ASA ()

-1(COX-1)( ) ,

American Diabetes Association

: (75-162 mg/dl) , (, , by pass, , / ). (75-162 mg/dl) 2 1 ( >40 , , , , ).

[ , ,

American Heart Association

: .

Circulation 2007:115;114-126

American Heart Association

Circulation 2007:115;114-126

(75-160 mg ), ( >10%, 10- ), 2.

European Heart Journal (2007) 28, 88-136

ESC GUIDELINES

- , 15% 25%

ETDRS(Early Treatment of Diabetic Retinopathy), :

3711 1 2

(650 mg ) vs ,

28% , (5-

EDTRS (Early Treatment of Diabetic Retinopathy)

BMJ. 1994, 15;308(6922):159-68.

HOT(Hypertension Optimal Treatment)

1501 :

(75 mg ) vs

, 15%, (

Lancet. 1998 13;351(9118):1755-62

18790

1501

Primary Prevention Project

Primary Prevention Project , (100 mg ) 10 , ,

ATC(Antiplatelet Trialists Collaboration)

- ATC(Antiplatelet Trialists Collaboration) , ,

BMJ. 1994, 15;308(6922):159-68

-ASA ()

(GP) IIb/

IIIa

ADP , , (P2Y12) ADP .

1 . . , , .

N Engl J Med. 1998, 3;339(23):1665-71.

2 ,

, ( , (PCI)

J Am Coll Cardiol. 2002, 2;39(1):9-14.

, non-ST (), ( 300 mg , 75 mg ) , .

PCI, 300 mg, 75 mg , 6-24

J Am Coll Cardiol. 2007, 14;50(7):e1-e157

Algorithm for Patients With UA/NSTEMI Managed by an Initial Invasive Strategy(AHA/ACC)

JACC Vol. 50, No. 7, 2007

Management After Diagnostic Angiography in Patients With UA/NSTEMI (AHA/ACC)

JACC Vol. 50, No. 7, 2007

Long-Term Anticoagulant Therapy at Hospital Discharge After UA/NSTEMI (AHA/ACC)

JACC Vol. 50, No. 7, 2007

CAPRIE(Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events)

1914

(75 mg ) vs (325 mg ).

19185

1914 (

)

A .

Lancet. 1996, 16;348(9038):1329-39

CURE(Clpidogrel in Unstable angina to prevent Recurrent Events)

- vs

()

17%, , , .

12562

non-ST 2840

N Engl J Med. 2001, 16;345(7):494-502

ST (),

300 mg , 75 mg , 12

.

CLARITY(Clopidogrel as Adjunctive Reperfusion Therapy)

Best Pract Res Clin Endocrinol Metab. 2009;23(3):375-88Wien Med Wochenschr. 2010;160(1-2):30-8

2009 (FDA) (PCI), .

,

TRITON-TIMI 38(The Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel)

13608 PCI :

60 mg ( ) 10 mg ( )

vs

300 mg ( ) 75 mg ( ) 14,5

- (n=3146), 40% , - -

Lancet. 2009, 28;373(9665):723-31

Wien Med Wochenschr2010 Jan;160(1-2):30-8

-ASA ()

(GP) IIb/

IIIa

(GP) IIb/IIIa

(GP) IIb/IIIa, GP IIb/IIIa , .

() , PCI( stent), /

Circulation. 2001, 4;104(23):2767-71

(GP) IIb/IIIa

(GP) IIb/IIIa

EPILOG(Evaluation in PTCA to Improve Long-term Outcome with Abciximab GP IIb/IIIa blockade)

Circulation 1998;97;1912-1920

EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial)

PCI, O, 6 PCI, .

Circulation 1999;100;2477-2484

.

CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications ) ,

(GP) IIb/IIIa

Am J Cardiol. 2004, 15;94(8):983-8

ISAR-REACT 2, non-ST , PCI (600 mg, )

30 .

ISAR-REACT 2 (Intracoronary Stenting and Antithrombotiv: Regimen Rapid Early Action for Coronary Treatment 2)

Curr Opin Endocrinol Diabetes Obes. 2007;14(2):124-31

-ASA ()

(GP) IIb/

IIIa

cAMP, 2 (TXA2) .

.

, :

+

+

Clin Res Cardiol. 2010 Nov;99(11):743-52

, ,